The similar drugs: an exploratory study on their introduction before COVID-19 in the Mexican market

Abstract

This study analyzed the manufacturing process, origin, characteristics, and distribution of similar drugs to understand their impact and key differences within the Mexican pharmaceutical market. The methodology employed was exploratory and descriptive, based on collecting qualitative information supported by quantitative data, including an exhaustive ten-year review of the state of the art. The designation "similar" was coined by Farmacias Similares as a commercial differentiation strategy. Findings revealed that, although the Ministry of Health does not legally define them, commercially they are identified as generics that have not undergone mandatory bioequivalence and bioavailability testing. The success and high consumption of this commercial proposition are primarily explained by the affordability of their prices compared to other medications on the market, establishing an innovative business model in Mexico.